Relief Therapeutics Appoints Drew Cronin-Fine as Executive Director, Head of U.S. Marketing

Get instantaneous alerts when information breaks in your shares. Claim your 1-week free trial to RoadInsider Premium right here.

Proven Pharmaceutical Marketing Leader Brings Extensive Experience in Rare Diseases, Digital Innovation and New Product Launches to Relief’s U.S. Commercial Team GENEVA, SWITZERLAND / ACCESSWIRE / April 26, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB: RLFTF)(OTCQB: RLFTY) (“Relief”), a biopharmaceutical firm searching for to offer sufferers therapeutic reduction from severe ailments with excessive unmet want, introduced at present the appointment, efficient May 3, 2022, of Drew Cronin-Fine as Executive Director, Head of U.S. Marketing. In this newly created place, Ms. Cronin-Fine can be liable for constructing and main the U.S. Marketing crew. She will report back to Anthony Kim, Senior Vice President and Head of U.S. Commercial Operations.”Drew’s addition to the corporate displays our continued dedication to constructing out our U.S. business crew in anticipation of the rollout of PKU GOLIKE(R), the flagship product line of our wholly owned subsidiary, APR Applied Pharma Research, SA (APR), and the upcoming June 5, 2022 Prescription Drug User Fee Act (PDUFA) date and potential launch of ACER-001 to deal with Urea Cycle Disorders, in collaboration with Acer Therapeutics,” said Mr. Kim. “Drew’s success in launching quite a few merchandise within the uncommon illness area, as effectively as her confirmed abilities in digital expertise and crew constructing, gained from her tenures at Intercept Pharmaceuticals and Cubist Pharmaceuticals, make her a key member of the U.S. business crew as we optimize our rising uncommon illness pipeline.””My ardour for enhancing the lives of sufferers with uncommon ailments, coupled with the chance to be half of the launch of potential new merchandise within the U.S., had been key components that drew me to this thrilling position at Relief Therapeutics,” added Ms. Cronin-Fine. “I sit up for becoming a member of the rising business crew at Relief and being an integral half of its mission to develop therapeutics for severe ailments with few or no current therapy choices.”Prior to becoming a member of Relief, for the previous seven years, Ms. Cronin-Fine held quite a few positions of rising duty in U.S. Marketing at Intercept Pharmaceuticals, Inc. As Executive Director, she led the U.S. Marketing division for OCALIVA(R), indicated to be used in main biliary cholangitis, an orphan liver illness. While at Intercept, her tasks included overseeing the healthcare practitioner, affected person, market entry, and digital advertising methods. From 2012 to 2015, Ms. Cronin-Fine labored at Cubist Pharmaceuticals (subsequently acquired by Merck), most not too long ago serving as Associate Director, U.S. Marketing, the place she managed the U.S. market analysis, market entry, and forecasting funds plan for ZERBAXA(R), a gram-negative anti-infective drug. Earlier in her profession, from 2006 to 2011, Ms. Cronin-Fine was Co-founder and Chief Operating Officer of Zinuara Pharma, an organization targeted on the scientific growth of Huperzine A, for the therapy of epilepsy and ache. She additionally served as a advisor and analyst at IMS Consulting (now IQVIA) within the pricing and reimbursement group.Ms. Cronin-Fine earned a Bachelor of Science diploma from Brown University, a Master of Business Administration diploma from Harvard Business School, and a Master of Science from the Harvard-MIT Division of Health Sciences and Technology.ABOUT RELIEFRelief focuses totally on clinical-stage packages based mostly on molecules with a historical past of scientific testing and use in human sufferers or a powerful scientific rationale. Relief’s drug candidate, RLF-100(R) (aviptadil), an artificial type of Vasoactive Intestinal Peptide (VIP), is in late-stage scientific testing within the U.S. for the therapy of respiratory deficiency resulting from COVID-19 by way of Relief’s collaboration accomplice within the U.S., NeuroRx, Inc. Relief additionally has a Collaboration and License Agreement with Acer Therapeutics for the worldwide growth and commercialization of ACER-001, a taste-masked and instant launch proprietary powder formulation of sodium phenylbutyrate (NaPB) for the therapy of Urea Cycle Disorders and Maple Syrup Urine Disease. Acer’s new drug utility for ACER-001 to be used as a therapy of urea cycle problems was not too long ago accepted by the FDA for submitting with a PDUFA resolution date of June 5, 2022. Finally, Relief’s acquisitions final summer time of APR Applied Pharma Research SA and AdVita Lifescience GmbH dropped at Relief a various pipeline of marketed and development-stage packages.RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange beneath the image RLF and quoted within the U.S. on OTCQB beneath the image RLFTF. For extra info, go to Follow us on LinkedIn.CONTACT:RELIEF THERAPEUTICS Holding SAJack WeinsteinChief Financial Officer and Treasurer[email protected]FOR MEDIA/INVESTOR INQUIRIES:Rx Communications GroupMichael Miller+1-917-633-6086[email protected]Disclaimer: This communication expressly or implicitly comprises sure forward-looking statements regarding RELIEF THERAPEUTICS Holding SA. Such statements contain sure identified and unknown dangers, uncertainties and different components, together with these dangers mentioned in RELIEF THERAPEUTICS Holding SA’s press releases and filings with the SIX and with the U.S. Securities and Exchange Commission, which might trigger the precise outcomes, monetary situation, efficiency or achievements of RELIEF THERAPEUTICS Holding SA to be materially totally different from any future outcomes, efficiency or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding SA is offering this communication as of this date and doesn’t undertake to replace any forward-looking statements contained herein as a outcome of new info, future occasions or in any other case.SOURCE: Relief Therapeutics Holdings AGView supply model on

Recommended For You